Carillon Séverine, Gallardo Lucille, Linard Françoise, Chakvetadze Catherine, Viard Jean-Paul, Cros Agnès, Molina Jean-Michel, Slama Laurence
CEPED, IRD, Paris Descartes University, Paris, France.
Infectious Diseases Unit, Hôtel Dieu Hospital, Paris, France.
AIDS Care. 2020 May;32(sup2):155-161. doi: 10.1080/09540121.2020.1742869. Epub 2020 Mar 19.
Recent clinical trial data showed that injectable long-acting antiretroviral treatment (LA-ART) every four or eight weeks could become an alternative option for HIV treatment or prevention. The purpose of our study was to explore perceptions and potential users' points of views of this new mode of administration through individuals' therapeutic itinerary and their singular history with ART. Between 2018 and 2019, a qualitative study was conducted in two University Hospitals in Paris, France. In-depth interviews were conducted with 15 virologically controlled People Living with HIV (PLWH) and 13 men on pre-exposure prophylaxis (PrEP) for at least six months. Interviews, focused on the daily experience with ART, were recorded, transcribed, and analyzed using thematic content analysis. Collected discourses were organized around three emergent concerns: social, material and experimental. Each of these concerns was perceived as ambivalent, balanced by skepticism and hope. It revealed the complexity of each individual's relationship to their HIV treatment or PrEP, leading to balance the injectable LA-ART popularity reported within clinical trials. This new mode of administration may be a suitable alternative for some PLWH and PrEP users, a "simplification" compared to the oral route. It opens a window for "customizable" ART-treatment according to individuals' lives.
近期临床试验数据表明，每四周或八周进行一次长效抗逆转录病毒注射治疗（LA-ART）可能成为治疗或预防HIV的一种替代选择。我们研究的目的是通过个人的治疗历程以及他们接受抗逆转录病毒治疗（ART）的独特经历，探索对这种新给药方式的看法以及潜在使用者的观点。2018年至2019年期间，在法国巴黎的两家大学医院开展了一项定性研究。对15名病毒学得到控制的HIV感染者（PLWH）以及13名接受暴露前预防（PrEP）至少六个月的男性进行了深入访谈。访谈聚焦于ART的日常体验，访谈内容进行了录音、转录，并采用主题内容分析法进行分析。收集到的话语围绕三个新出现的关注点展开：社会、物质和试验。这些关注点中的每一个都被认为具有矛盾性，受到怀疑和希望的平衡。这揭示了每个人与他们的HIV治疗或PrEP关系的复杂性，导致在临床试验中报道的长效抗逆转录病毒注射治疗的受欢迎程度需保持平衡。这种新的给药方式可能对一些PLWH和PrEP使用者来说是一种合适的替代选择，与口服途径相比是一种“简化”。它为根据个人生活“定制”抗逆转录病毒治疗打开了一扇窗。
